Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30896324 | 0.86 | GAA (0.51) | GAAMAPTLMNAHPGDGRIN2D | |
| SCHEMBL14819940 | 0.86 | GAA (0.51) | GAAMAPTLMNAHPGDGRIN2D | |
| SCHEMBL7478895 | 0.86 | GAA (0.51) | GAAMAPTLMNAHPGDTSHR | |
| SCHEMBL2004172 | 0.86 | GAA (0.51) | GAAMAPTLMNAHPGDCYP3A4 | |
| SCHEMBL13544185 | 0.86 | MAPT (0.54) | GAAMAPTLMNAHPGDCYP3A4 | |
| SCHEMBL7478904 | 0.86 | GAA (0.51) | GAAMAPTLMNAHPGDCYP3A4 | |
| SCHEMBL7475993 | 0.84 | GAA (0.49) | GAAMAPTPOLBALDH1A1TDP1 | |
| SCHEMBL7475985 | 0.84 | GAA (0.49) | GAAMAPTCYP3A4BLMPOLB | |
| SCHEMBL4364726 | 0.80 | GAA (0.59) | GAAMAPTLMNAHPGDCYP3A4 | |
| SCHEMBL28118863 | 0.77 | GAA (0.56) | GAAMAPTLMNAHPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470827-B2 | Composition for the vapor phase dehydrohalogenation of 1,1,2-trihaloethane to 1,1-dihaloethylene and methods for preparing and using such composition | PPG INDUSTRIES OHIO, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080242902-A1 | Composition For the Vapor Phase Dehydrohalogenation of 1,1,2-Trihaloethane To 1,1-Dihaloethylene and Methods For Preparing and Using Such Composition | PPG INDUSTRIES OHIO, INC (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2006132625-A1 | COMPOSITION FOR THE VAPOR PHASE DEHYDROHALOGENATION OF 1,1,2-TRIHALOETHANE TO 1,1-DIHALOETHYLENE AND METHODS FOR PREPARING AND USING SUCH COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6656940-B2 | Treatment of cancer. | SUGEN, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6329375-B1 | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | SUGEN, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-1999007701-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | SUGEN, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | GAA 1411/4885MAPT 3699/4885LMNA 3816/4885 |
| US-20080242902-A1 | Composition For the Vapor Phase Dehydrohalogenation of 1,1,2-Trihaloethane To 1,1-Dihaloethylene and Methods For Preparing and Using Such Composition | CYP2E1, CYP1A1, HDHD5 | GAA 1157/4885MAPT 3595/4885LMNA 4247/4885 |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | GAA 1411/4885MAPT 3699/4885LMNA 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.